Related Experiment Videos
Chemotherapy for ovarian cancer: current concepts
1Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
Seminars in Surgical Oncology
|October 3, 1999
Summary
Evolving chemotherapy for ovarian cancer, particularly taxane/platinum combinations, has significantly improved patient survival rates. Ongoing research explores optimal dosing and administration for this common gynecologic malignancy.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Ovarian cancer is a leading cause of cancer death among women.
- Chemotherapy has historically offered limited efficacy for epithelial ovarian carcinoma.
- Treatment paradigms have advanced significantly over the past 15 years.
Purpose of the Study:
- To provide an overview of the evolution of chemotherapy for epithelial ovarian cancer.
- To highlight the development of current standards of care.
- To discuss unresolved issues and future directions in treatment.
Main Methods:
- Review of historical and recent clinical trials in ovarian cancer chemotherapy.
- Analysis of the impact of combination chemotherapy regimens.
- Evaluation of platinum compounds and taxanes in treatment protocols.
Main Results:
- Combination chemotherapy demonstrated superiority over single-agent therapy.
- Platinum compounds improved response rates, becoming a standard with alkylating agents.
- Taxane/platinum combination chemotherapy is now the established standard of care, showing improved response rates and prolonged survival.
Conclusions:
- The current standard of care for epithelial ovarian cancer is taxane/platinum combination chemotherapy.
- Further research is needed on optimal dosing, infusion times, and platinum compound interchangeability.
- Intraperitoneal chemotherapy and dose intensification remain areas for investigation.